Your cart is empty.
Männedorf, Switzerland, April 16, 2015 - The Annual General Meeting of Tecan Group Ltd. (SIX Swiss Exchange: TECN) has today endorsed all motions proposed by the Board of Directors. Shareholders approved the Annual Report, the financial statements and the consolidated financial statements, and granted discharge to the Board of Directors and the Management Board. They also approved a dividend of CHF 1.50 per registered share, unchanged versus the previous year. The payout will take place on April 22, 2015.
All members of the Tecan Board of Directors who stood for re-election were confirmed by the shareholders for a term of one year: Heinrich Fischer, Dr. Oliver Fetzer, Dr. Karen Huebscher, Dr. Christa Kreuzburg, Gérard Vaillant and Rolf Classon. Rolf Classon was re-elected as Chairman of the Board of Directors. The shareholders also confirmed Oliver Fetzer and Christa Kreuzburg as members of the Compensation Committee.
The Annual General Meeting elected Lars Holmqvist as a new member of the Board of Directors. Lars Holmqvist, 56, a Swedish national, brings more than 25 years' international experience within the medical device, pharmaceutical and life science industries, where he held roles in marketing, sales and business management. Most recently, he was President of the Life Sciences and Diagnostics Group and Senior Vice President at Agilent Technologies Inc.
The Chairman bid farewell to Erik Walldén, who decided not to stand for re-election after four years on the Board of Directors, and thanked him for his valuable service.
KPMG AG, Zurich, was reappointed as the statutory auditors for fiscal 2015.
Shareholders approved the motion proposed by the Board of Directors to appoint Proxy Voting Services GmbH, Zurich, as the independent proxy for the period up to the close of the Tecan Group 30th Annual General Meeting in 2016.
All proposals relating to compensation approved
For the first time, shareholders voted on the conditions governing the compensation of the Board of Directors and Management Board for the following fiscal year, in line with the amendments to the Articles of Incorporation adopted in the previous year. The Company submitted two separate proposals to the Annual General Meeting for the Management Board. One of these proposals concerned the fixed salary and additional components relating to fiscal 2016. The second proposal related to Tecan Group's existing long-term incentive plan. The shareholders made a binding decision to endorse all proposed motions on the maximum total amount of compensation for 2016. The compensation report, which was submitted for an advisory vote for the fourth time, was also accepted by shareholders.
Next key date
Tecan will publish the 2015 Interim Report on August 12, 2015.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2014, Tecan generated sales of CHF 400 million (USD 437 million; EUR 331 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89